Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	26.47	37.27	58.8	33.11	7.52
Cash & Cash Equivalents	26.47	37.27	58.8	33.11	7.52
Cash Growth	-28.96%	-36.63%	77.61%	340.36%	169.27%
Receivables	0	0	0	0.56	0.64
Other Current Assets	2.62	2.91	0.52	0.35	0.12
Total Current Assets	29.09	40.18	59.32	34.02	8.28
Property, Plant & Equipment	2.12	0.62	0.93	1.09	1.11
Goodwill and Intangibles	0	0	19.09	19.09	19.09
Other Long-Term Assets	0.05	0.05	0.05	0.05	0.05
Total Long-Term Assets	2.17	0.66	20.07	20.23	20.25
Total Assets	31.26	40.84	79.39	54.24	28.53
Accounts Payable	3.02	0.98	1.3	1.08	2
Current Debt	0.24	0.24	0.24	0.22	0.28
Other Current Liabilities	0	0	0.01	0.06	0.01
Total Current Liabilities	3.26	1.22	1.55	1.36	2.29
Long-Term Debt	1.61	0.06	0.3	0.38	0.54
Total Long-Term Liabilities	1.61	0.06	0.3	0.38	0.54
Total Liabilities	4.88	1.27	1.84	1.74	2.82
Total Debt	1.85	0.3	0.53	0.6	0.82
Debt Growth	523.91%	-44.38%	-10.40%	-27.05%	146.83%
Retained Earnings	-315.91	-297.93	-259.09	-244.91	-235.26
Shareholders' Equity	26.38	39.57	77.55	52.51	25.71
Net Cash / Debt	24.62	36.97	58.27	32.51	6.7
Net Cash / Debt Growth	-33.40%	-36.55%	79.23%	385.15%	172.29%
Net Cash Per Share	2.55	4.54	7.91	7.07	2.52
Working Capital	25.83	38.96	57.78	32.66	6
Book Value Per Share	2.73	4.86	10.53	11.41	9.68

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).